Antibodies to the three major glycoproteins of varicella-zoster virus: search for the relevant host immune response
- PMID: 3039010
- DOI: 10.1093/infdis/156.3.430
Antibodies to the three major glycoproteins of varicella-zoster virus: search for the relevant host immune response
Abstract
Clinical manifestations of chickenpox have occurred in individuals known to have seroconverted after vaccination against varicella. To determine whether these "breakthroughs" might be due to the absence of specific antibodies, we tested sera from vaccinees before or at the time of exposure to varicella for antibodies to the three major glycoproteins of varicella-zoster virus (VZV). Protection could not be correlated with the presence or level of any of these antibodies. Levels of antibodies to glycoproteins before onset of zoster were similar to those in sera of individuals who had had varicella previously and did not develop varicella after household exposure. Thus, protection against infections with VZV cannot be explained by the presence of specific antibodies to glycoproteins.
Similar articles
-
Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.J Virol. 2018 Jun 29;92(14):e00269-18. doi: 10.1128/JVI.00269-18. Print 2018 Jul 15. J Virol. 2018. PMID: 29743372 Free PMC article.
-
Antibodies to varicella-zoster virus glycoproteins I, II, and III in leukemic and healthy children.J Infect Dis. 1990 Sep;162(3):627-33. doi: 10.1093/infdis/162.1.627. J Infect Dis. 1990. PMID: 2167335
-
Western blot analysis of antibody to varicella-zoster virus.J Infect Dis. 1988 May;157(5):882-8. doi: 10.1093/infdis/157.5.882. J Infect Dis. 1988. PMID: 2834466
-
Cell-mediated immunity to varicella-zoster virus.J Infect Dis. 1992 Aug;166 Suppl 1:S35-41. doi: 10.1093/infdis/166.supplement_1.s35. J Infect Dis. 1992. PMID: 1320649 Review.
-
The effect of vaccination on the epidemiology of varicella zoster virus.J Infect. 2002 May;44(4):211-9. doi: 10.1053/jinf.2002.0988. J Infect. 2002. PMID: 12099726 Review.
Cited by
-
A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.Blood. 2014 Nov 6;124(19):2921-9. doi: 10.1182/blood-2014-04-573048. Epub 2014 Sep 18. Blood. 2014. PMID: 25237196 Free PMC article. Clinical Trial.
-
Cross-reactive humoral immunity of clade 2 Oka and MAV/06 strain-based varicella vaccines against different clades of varicella-zoster virus.Hum Vaccin Immunother. 2023 Dec 31;19(1):2210961. doi: 10.1080/21645515.2023.2210961. Epub 2023 May 23. Hum Vaccin Immunother. 2023. PMID: 37218543 Free PMC article.
-
COMMENTARY: Significantly less anti-gC antibody detectable in sera collected after varicella vaccination than after the disease varicella.Pediatr Infect Dis J. 2012 Nov;31(11):1153-4. doi: 10.1097/INF.0b013e31826ef456. Pediatr Infect Dis J. 2012. PMID: 23069796 Free PMC article.
-
Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.J Virol. 2018 Jun 29;92(14):e00269-18. doi: 10.1128/JVI.00269-18. Print 2018 Jul 15. J Virol. 2018. PMID: 29743372 Free PMC article.
-
Acyclovir treatment for varicella does not lower gpI and IE-62 (p170) antibody responses to varicella-zoster virus in normal children.J Clin Microbiol. 1990 Oct;28(10):2327-30. doi: 10.1128/jcm.28.10.2327-2330.1990. J Clin Microbiol. 1990. PMID: 2172288 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical